Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer

Genotyping of a family with a novel deleteriousDPYDmutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio

(2015) F Thomas et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

(2015) Felicia Falvella et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients

(2015) Marzia Del Re et al.   EPMA Journal

Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy

(2014) Göran Carlsson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

(2014) Dan Rosmarin et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio

(2014) Johanna Sistonen et al.   PHARMACOGENOMICS

Influence ofDPYDGenetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis

(2014) Qiang Li et al.   Gastroenterology Research and Practice

DPYDIVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis

(2013) Salvatore Terrazzino et al.   PHARMACOGENOMICS

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

(2013) M C van Staveren et al.   PHARMACOGENOMICS JOURNAL

Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy

(2012) André B. P. van Kuilenburg et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetic Analysis of 5-FU and 5-FDHU in Colorectal Cancer Patients: Search for Biomarkers Associated with Gastro-Intestinal Toxicity

(2012) Christian Woloch et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency

(2011) Maurice C. van Staveren et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Time-Dependent Pharmacokinetics of 5-Fluorouracil and Association With Treatment Tolerability in the Adjuvant Setting of Colorectal Cancer

(2011) Toni Ibrahim et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The current landscape of locally advanced rectal cancer

(2011) Mebea Aklilu et al.   Nature Reviews Clinical Oncology

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

(2011) Ursula Amstutz et al.   PHARMACOGENOMICS

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

(2010) Chen Guang Yang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?

(2010) Joseph Ciccolini et al.   Clinical Colorectal Cancer

Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application

(2010) Soo-Youn Lee et al.   JOURNAL OF PATHOLOGY

Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction

(2008) Guido Bocci et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer

(2008) A. Di Paolo et al.   CLINICAL CANCER RESEARCH

Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer

(2008) Erick Gamelin et al.   JOURNAL OF CLINICAL ONCOLOGY